Active Implantable Medical Devices Market

Executive Summary

Active Implantable Medical Devices Market was valued at US $105.39 billion in 2021 and is projected to grow at 7.05% CAGR over the forecast period to reach US $158.60 billion by 2027. Active Implantable Medical Devices Market represented US $13.42 billion opportunity over 2019-2021 and estimated to create US $53.21 billion opportunity in 2027 over 2021.

Active Implantable Medical Devices from Consainsights analyses the Active Implantable Medical Devices Market in the Life Sciences industry over the forecast period to 2027.

Active Implantable Medical Devices research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Active Implantable Medical Devices segmentation includes Product, Region and Geography.

Based on the Product, the Active Implantable Medical Devices analysis covers Implantable Cardioverter Defibrillators, Implantable Cardiac Pacemakers, Ventricular Assist Devices, Implantable Heart Monitors/Insertable Loop Recorders, Neurostimulators, Implantable Hearing Devices.

In Product segment, Implantable Cardioverter Defibrillators segment has highest cagr growth of 6.24%.

Based on the Region, the Active Implantable Medical Devices analysis covers North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.

In Region segment, North America segment has highest cagr growth of 6.24%.

Based on the region, the Active Implantable Medical Devices analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include Abbott Laboratories, Medtronic PLC, Boston Scientific Corporation, Biotronik Se & Co., Kg, Livanova PLC, William Demant Holding A/S, Cochlear Limited, Sonova Holding AG, Med-El, Nurotron Biotechnology Co. Ltd. and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Product

Introduction

In 2021, Implantable Cardioverter Defibrillators segment has the highest revenue of US $41.18 billion and is expected to grow at CAGR of 6.24% by 2027 Implantable Cardioverter Defibrillators segment has highest cagr growth of 6.24%.

Implantable Cardioverter Defibrillators

Implantable Cardioverter Defibrillators segment was valued at US $35.94 billion in 2019 and is projected to grow at 6.24% CAGR over the forecast period to reach US $61.97 billion by 2027. Implantable Cardioverter Defibrillators segment represented US $5.24 billion opportunity over 2019-2021 and estimated to create US $20.79 billion opportunity in 2027 over 2021.

Implantable Cardiac Pacemakers

Implantable Cardiac Pacemakers segment was valued at US $23.28 billion in 2019 and is projected to grow at 6.24% CAGR over the forecast period to reach US $40.15 billion by 2027. Implantable Cardiac Pacemakers segment represented US $3.40 billion opportunity over 2019-2021 and estimated to create US $13.47 billion opportunity in 2027 over 2021.

Ventricular Assist Devices

Ventricular Assist Devices segment was valued at US $12.97 billion in 2019 and is projected to grow at 6.24% CAGR over the forecast period to reach US $22.36 billion by 2027. Ventricular Assist Devices segment represented US $1.89 billion opportunity over 2019-2021 and estimated to create US $7.50 billion opportunity in 2027 over 2021.

Implantable Heart Monitors/Insertable Loop Recorders

Implantable Heart Monitors/Insertable Loop Recorders segment was valued at US $8.45 billion in 2019 and is projected to grow at 6.24% CAGR over the forecast period to reach US $14.57 billion by 2027. Implantable Heart Monitors/Insertable Loop Recorders segment represented US $1.23 billion opportunity over 2019-2021 and estimated to create US $4.89 billion opportunity in 2027 over 2021.

Neurostimulators

Neurostimulators segment was valued at US $6.03 billion in 2019 and is projected to grow at 6.24% CAGR over the forecast period to reach US $10.39 billion by 2027. Neurostimulators segment represented US $0.88 billion opportunity over 2019-2021 and estimated to create US $3.49 billion opportunity in 2027 over 2021.

Implantable Hearing Devices

Implantable Hearing Devices segment was valued at US $5.31 billion in 2019 and is projected to grow at 6.24% CAGR over the forecast period to reach US $9.16 billion by 2027. Implantable Hearing Devices segment represented US $0.78 billion opportunity over 2019-2021 and estimated to create US $3.07 billion opportunity in 2027 over 2021.

Region

Introduction

In 2021, North America segment has the highest revenue of US $43.42 billion and is expected to grow at CAGR of 6.24% by 2027 North America segment has highest cagr growth of 6.24%.

North America

North America segment was valued at US $37.89 billion in 2019 and is projected to grow at 6.24% CAGR over the forecast period to reach US $65.34 billion by 2027. North America segment represented US $5.53 billion opportunity over 2019-2021 and estimated to create US $21.92 billion opportunity in 2027 over 2021.

Europe

Europe segment was valued at US $21.93 billion in 2019 and is projected to grow at 6.24% CAGR over the forecast period to reach US $37.82 billion by 2027. Europe segment represented US $3.20 billion opportunity over 2019-2021 and estimated to create US $12.69 billion opportunity in 2027 over 2021.

Asia-Pacific

Asia-Pacific segment was valued at US $13.62 billion in 2019 and is projected to grow at 6.24% CAGR over the forecast period to reach US $23.50 billion by 2027. Asia-Pacific segment represented US $1.99 billion opportunity over 2019-2021 and estimated to create US $7.88 billion opportunity in 2027 over 2021.

Latin America

Latin America segment was valued at US $9.30 billion in 2019 and is projected to grow at 6.24% CAGR over the forecast period to reach US $16.04 billion by 2027. Latin America segment represented US $1.36 billion opportunity over 2019-2021 and estimated to create US $5.38 billion opportunity in 2027 over 2021.

Middle East and Africa

Middle East and Africa segment was valued at US $9.22 billion in 2019 and is projected to grow at 6.24% CAGR over the forecast period to reach US $15.89 billion by 2027. Middle East and Africa segment represented US $1.35 billion opportunity over 2019-2021 and estimated to create US $5.33 billion opportunity in 2027 over 2021.